Skip to main content

Table 1 Summary of survey results

From: UK national clinical audit: management of pregnancies in women with HIV

Does your service have a dedicated HIV in pregnancy MDT?

 

Yes

111 (99%)

 

No

1 (1%)

Does this MDT include:

 

An HIV physician

112 (100%)

 

An obstetrician

111 (99%)

 

A paediatrician

110 (98%)

 

An HIV midwife

29 (26%)

 

An HIV clinical nurse specialist

21 (19%)

Following a new HIV diagnosis during antenatal screening, how quickly would you expect a women to be seen in the HIV clinic?

 

Same/next day

40 (36%)

 

2 – 3 days

23 (21%)

 

Within a week

29 (26%)

 

1 - 2 weeks

19 (17%)

 

Not answered

1 (1%)

Do you have a policy for the use of ART in pregnancy?

 

Yes

109 (97%)

 

No

2 (2%)

 

No response

1 (1%)

Would you use raltegravir in a women presenting after 28 weeks gestation with a VL > 100,000 copies/mL?

 

Use routinely

56 (50%)

 

May use

43 (38%)

 

No policy/has not arisen

11 (10%)

 

Would not use

1 (1%)

 

Not sure

1 (1%)

What arrangement do you have in place for urgent HIV testing for women presenting in labour, with ruptured membranes of requiring delivery with no result?

 

Arrangement for urgent lab test

95 (85%)

 

Point of care testing in all delivery units

15 (13%)

 

Urgent lab test not available

1 (1%)

 

Not sure

1 (1%)

Have you experienced problems with urgent HIV testing?

 

Problems experienced

10 (9%)

 

Provided without problems

40 (36%)

 

Need not arisen

55 (49%)

How long does it take to obtain an urgent HIV laboratory test result?

 

>2 h in working hours

21 (19%)

 

>2 h outside of working hours

56 (50%)

Do you have a policy on mode of delivery in HIV?

 

Yes

107 (96%)

 

No

2 (2%)

 

Not sure/not answered

3 (3%)

What mode of delivery would you recommend for those on ART with a VL <50 copies/mL at >36 weeks, and no relevant obstetric factors?

 

Planned vaginal delivery

95 (85%)

 

Maternal choice

9 (8%)

 

Pre-labour caesarean section

3 (3%)

 

Other/not answered

5 (5%)

  1. MDT multidisciplinary team, ART antiretroviral therapy